Zai Lab (ZLAB) Income from Continuing Operations (2018 - 2026)
Zai Lab (ZLAB) posted Income from Continuing Operations of 51016000.0 for Q1 2026, down 1.2% sequentially from 50409000.0 in Q4 2025, and down 5.32% YoY from 53883842.3 in Q1 2025.
Zai Lab (ZLAB) Income from Continuing Operations (2018 - 2026) Analysis & Trends
Zai Lab has reported Income from Continuing Operations for 9 years, with the latest figure at 51016000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 5.32% year-over-year to 51016000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 178115000.0 (up 29.34% YoY) and the FY2025 annual result came in at 175537000.0, up 31.73% from the prior year.
- Income from Continuing Operations retreated to 51016000.0 in Q1 2026 per ZLAB's latest filing, from 50409000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 35963000.0 in Q3 2025 and troughed at 161190000.0 in Q3 2022.
- A 5-year average of 74196529.41 and a median of 61769000.0 in 2022 frame the typical range for Income from Continuing Operations.
- The widest YoY moves for Income from Continuing Operations: up 70.77% in 2022, down 67.78% in 2022.
- Over 5 years, Income from Continuing Operations stood at 61769000.0 in 2022, then plunged by 54.49% to 95429000.0 in 2023, then increased by 14.4% to 81684000.0 in 2024, then surged by 38.29% to 50409000.0 in 2025, then declined by 1.2% to 51016000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 51016000.0, 50409000.0, and 35963000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Zai Lab | 2.91 Bn | 2.20 Bn | 58.15 Mn | -50.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -50.83 Mn |
| Mar 31, 2026 | -51.02 Mn |
| Dec 31, 2025 | -50.41 Mn |
| Sep 30, 2025 | -35.96 Mn |
| Jun 30, 2025 | -40.73 Mn |
| Mar 31, 2025 | -48.44 Mn |
| Dec 31, 2024 | -81.68 Mn |
| Sep 30, 2024 | -41.67 Mn |
| Jun 30, 2024 | -80.28 Mn |
| Mar 31, 2024 | -53.47 Mn |
| Dec 31, 2023 | -95.43 Mn |
| Sep 30, 2023 | -69.15 Mn |
| Jun 30, 2023 | -120.90 Mn |
| Mar 31, 2023 | -49.14 Mn |
| Dec 31, 2022 | -61.77 Mn |
| Sep 30, 2022 | -161.19 Mn |
| Jun 30, 2022 | -137.93 Mn |
| Mar 31, 2022 | -82.17 Mn |
| Dec 31, 2021 | -211.32 Mn |
| Sep 30, 2021 | -96.07 Mn |